Webinar: Update on interventions to improve glycaemic control in type 2 diabetes


Webinar: Update on interventions to improve glycaemic control in type 2 diabetes

Presented by Gary Kilov
3 minutes to Read + 60 minutes to Watch
Webinar 1 Hyperglycaemia

This webinar updates viewers on the importance of glycaemic control for reducing the risk of complications from type 2 diabetes. It is the first in a series of webinars on the management of diabetes, brought to you with the support of Sanofi

This activity has been endorsed by the Pharmaceutical Society of New Zealand as suitable for inclusion in a pharmacist’s continuing education records for continuing professional development purposes. You can record details of this webinar on the “Keeping up to date” page of your portfolio on MyRecert (myrecert.pharmacycouncil.org.nz).

Watch the webinar

This webinar is presented by associate professor Gary Kilov and has the following learning objectives:

  • Detail the rationale behind timely and effective treatment escalation in type 2 diabetes
  • Understand type 2 diabetes treatment inertia and its contributing factors
  • Individualise glycaemic targets and personalise therapies according to clinical and personal factors


After you have watched this presentation, you may complete the assessment below to test your understanding of the topic.

Remember, you can also use the Capture button below to record your time spent watching.

    This is the first webinar in a series on the management of diabetes.

    Watch the second webinar in this series: Insulin therapy for patients with type 2 diabetes

    Watch the third webinar in this series: Practical management for patients with diabetes

    Watch the fourth webinar in this series: Intensifying insulin therapy for people with type 2 diabetes


    This eight-question multiple-choice assessment is designed to demonstrate that the webinar has been effective in allowing you to meet the learning objectives of this course. Write down your answers to these questions.

    1. Which TWO of the following are consequences of not escalating treatment early in type 2 diabetes?
    a. A vicious metabolic memory, which is not reversed by intensive glycaemic control
    b. A virtuous legacy effect, which provides protection over the longer term
    c. Accumulation of a bad glycaemic legacy, which drives risk of complications
    d. An increased risk of microvascular complications, but no difference in long-term macrovascular complications
    e. An increased risk of macrovascular disease, which can be reversed by intensive glycaemic control

    2. In the context of diabetes (glycaemia), what is therapeautic inertia?
    a. Failure to achieve an HbA1c target of <7% (53mmol/mol)
    b. Failure to commence or intensify therapy despite failing to achieve the agreed upon HbA1c goal
    c. Failure of specialist services to cope with increases in diabetes-related workload
    d. Failure of treatment to reduce microvascular and macrovascular complications

    3. What is the biggest contributor to therapeutic inertia in diabetes?
    a. Patient-level barriers
    b. Provider-level barriers
    c. System-level barriers
    d. Treatment-level barriers

    4. Which TWO of the following are system-level barriers that contribute to therapeutic inertia in diabetes?
    a. Healthcare access and costs
    b. Lack of knowledge and experience
    c. Limited availability of new medications
    d. Variations in guideline recommendations

    5. It is important to establish an indvidualised HbA1c target as part of the patient-centred approach to glycaemic management in type 2 diabetes. Which of the following patients should be treated most aggressively, aiming for a low HbA1c level?
    a. A patient with established vascular complications
    b. A patient with low motivation or depression
    c. A young patient with an absence of comorbidities
    d. An older patient with long-standing diabetes

    6. What is recommended by the American Diabetes Association and European Association for the Study of Diabetes for first-line glycaemic control in type 2 diabetes?
    a. Exercise and weight loss
    b. Metformin and comprehensive lifestyle modification
    c. Metformin and/or insulin
    d. SGLT2 inhibitor or GLP-1 receptor agonist

    7. The choice of second-line medication to be added to metformin is based on patient preference and clinical characteristics. According to guidelines from the American Diabetes Association and European Association for the Study of Diabetes, what is the preferred glucose-lowering medication(s) to add to metformin for those with established atherosclerotic cardiovascular disease?
    a. DPP-4 inhibitor
    b. GLP-1 receptor agonist or SGLT2 inhibitor
    c. Insulin
    d. Sulfonylurea
    e. Thiazolidinedione

    8. Which TWO of the following statements regarding weight loss in diabetes are correct?
    a. Medical nutrition therapy is less effective than medications for improving glycaemic control
    b. Metabolic surgery should only be considered for patients with diabetes and severe obesity (BMI ≥40.0kg/m2)
    c. There is a linear relationship between weight loss and HbA1c reduction
    d. Type 2 diabetes of more than two years’ duration cannot be reversed by weight loss
    e. Weight management within primary care can achieve remission of type 2 diabetes

    Write down your answers to these questions. Then, to check your answers and record your score, click here.